{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:53:59Z","timestamp":1792061639441,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":2785,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Sciences Journal"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.24920\/31805","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T03:14:56Z","timestamp":1531710896000},"page":"183-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Cancer: A Case Report"],"prefix":"10.1016","volume":"33","author":[{"given":"Zhimei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.24920\/31805_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.24920\/31805_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.24920\/31805_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.24920\/31805_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.24920\/31805_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.24920\/31805_bib6","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"10.24920\/31805_bib7","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.24920\/31805_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.24920\/31805_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.24920\/31805_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrc2587","article-title":"Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype","volume":"9","author":"Barnett","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.24920\/31805_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.soncn.2011.02.009","article-title":"Evidence-based skin care management in radiation therapy: clinical update","volume":"27","author":"McQuestion","year":"2011","journal-title":"Semin Oncol Nurs"},{"issue":"3 Pt 2","key":"10.24920\/31805_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/jid.2011.411","article-title":"Ionizing radiation: the good, the bad, and the ugly","volume":"132","author":"Ryan","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"26","key":"10.24920\/31805_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.24920\/31805_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.24920\/31805_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.24920\/31805_bib16","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.24920\/31805_bib17","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.24920\/31805_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.24920\/31805_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40257-016-0186-4","article-title":"Radiodermatitis: a review of our current understanding","volume":"17","author":"Singh","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.24920\/31805_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/09553002.2013.765055","article-title":"Mechanisms of radiation-induced skin injury and implications for future clinical trials","volume":"89","author":"Kim","year":"2013","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"10.24920\/31805_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1534735413490235","article-title":"The use of antioxidants in radiotherapy-induced skin toxicity","volume":"13","author":"Amber","year":"2014","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"10.24920\/31805_bib22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/jid.2008.360","article-title":"Pravastatin limits radiation-induced vascular dysfunction in the skin","volume":"129","author":"Holler","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.24920\/31805_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/15384047.2017.1345389","article-title":"A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma","volume":"18","author":"Xie","year":"2017","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"10.24920\/31805_bib24","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.jtho.2017.04.029","article-title":"Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung","volume":"12","author":"Yuan","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.24920\/31805_bib25","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1097\/MD.0000000000005747","article-title":"Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.24920\/31805_bib26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.autrev.2010.06.011","article-title":"The late news on baff in autoimmune diseases","volume":"9","author":"Youinou","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.24920\/31805_bib27","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.174.9.5537","article-title":"BAFF augments certain Th1-associated inflammatory responses","volume":"174","author":"Sutherland","year":"2005","journal-title":"J Immunol"},{"issue":"6","key":"10.24920\/31805_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.24920\/31805_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.24920\/31805_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous complications of targeted melanoma therapy","volume":"17","author":"de Golian","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.24920\/31805_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"}],"container-title":["Chinese Medical Sciences Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929418300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929418300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/cmsj.cams.cn\/previewFile?fileName=Treatment%20of%20Skin%20Reaction%20Induced%20by%20Nivolumab%20Combined%20with%20Radiotherapy%20in%20Non-small%20Cell%20Lung%20Cancer%3A%20A%20Case%20Report&id=56213165&type=pdf&lang=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:31:27Z","timestamp":1792060287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1001929418300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1001929418300439"],"URL":"https:\/\/doi.org\/10.24920\/31805","relation":{},"ISSN":["1001-9294"],"issn-type":[{"value":"1001-9294","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Cancer: A Case Report","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Sciences Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.24920\/31805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Chinese Academy Medical Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}